Celemics partners with Strand Life Science to develop bioinformatics solutions

Celemics has partnered with Strand Life Sciences to develop a bioinformatics solution capable of providing users with an accelerated means of producing high-quality, in-class clinical genomics reports and enabling a complete sample-to-answer solution, including assayspecific variant filters.

Algorics acquires Domain Clinical Data Sciences

Algorics, a provider of biostatistics and programming solutions for the pharmaceutical and biotechnology industry, has acquired Domain Clinical Data Sciences (DCDS), a clinical data services organisation based in India.

amsbiopr291

AMSBIO releases Adeno-Associated Virus reference materials

AMSBIO has unveiled a new range of AAV reference materials of full capsids and empty capsids of six different serotypes.

Abviris

Investors inject €2 million into Abviris to boost HPV cancer biomarker expansion

Abviris Deutschland, a biotech company, has received an injection of €2 million from existing investors to speed up expansion. The move comes after the publication of highly promising results for its pioneering immunoassay biomarker as an aid in the early diagnosis of head, neck and anogenital cancers caused by human papilloma viruses (HPV).

shutterstock 1704274843

Advances in point-of-care hematology analysis

Point-of-care hematology analysis can help to generate the data needed to make decisions about patient care quickly, both of which can improve patient outcomes in emergency situations and also help hospitals to meet waiting time targets safely. CLI asked Cleve Wright, Director of Medical HORIBA UK Ltd, about recent developments in this field.

agilent exon

Agilent announces new SureSelect Human All Exon V8

Agilent Technologies has released SureSelect Human All Exon V8 – a new exome design that provides comprehensive content and up-to-date coverage of protein-coding regions from RefSeq, CCDS, and GENCODE. It also covers the TERT promoter and hard-to-capture exons that are omitted by other exomes on the market. The new design is available in three options […]

actim Oy

Actim Oy antigen test for diagnosis of acute COVID-19 infection receives CE marking

The Finnish diagnostics company Actim Oy has recently received a CE mark for the new Actim SARS-CoV-2 rapid test. The test is intended for healthcare professionals and it detects the nucleoprotein of SARS-CoV-2 virus in the nasopharyngeal swab sample. The test has been shown to perform reliably with different variants of the coronavirus, such as […]

groen Fig 1 QuantiVac Correlation WHO Standard kopiëren 1

Investigation of SARS-CoV-2-specific immune responses

A thorough understanding of the immune response to SARS-CoV-2 is necessary for the evaluation of the efficacy of vaccines and vaccine candidates against this virus. This article discusses how some parts of the humoral and cellular immune responses can be analysed to improve our understanding of how the body reacts to this virus.

bruker tims

Bruker Corp launches two new timsTOF instruments

Bruker Corporation has launched two new timsTOF instruments – the timsTOF SCP for unbiased single cell 4D-proteomics and the next-gen timsTOF Pro 2 with unprecedented proteomic depth. The instruments enable new applications and methods in unbiased proteomics, epiproteomics/PTM characterization, and unbiased, deep multiomic biomarker discovery, such as in cancer liquid biopsy research.

hr PAN0069 CLI magazine nr. 3 2021 page by page Pagina 40

Enhanced performance